Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.
Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0.5-11.6%). RMP-resistant isolates that  were INH-susceptible had significantly lower rates of resistance to other first- and second-line anti-tuberculosis drugs (except rifabutin) compared to multidrug-resistant isolates. RMP resistance is not always a good proxy for a presumptive diagnosis of multidrug-resistant TB, which has implications  for use of molecular assays that identify only RMP resistance-associated DNA mutations.
Kurbatova, International Research and Programs Branch, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. ekurbatova@cdc.gov
E V
EV
Kurbatova
J S
JS
Cavanaugh
N S
NS
Shah
A
A
Wright
H
H
Kim
B
B
Metchock
A
A
Van Deun
L
L
Barrera
F
F
Boulahbal
E
E
Richter
N
N
Martín-Casabona
F
F
Arias
I
I
Zemanova
F
F
Drobniewski
A
A
Santos Silva
C
C
Coulter
R
R
Lumb
J P
JP
Cegielski
D000995:Antitubercular Agents / Q000494:pharmacology*; D004252:DNA Mutational Analysis / Q000379:methods; D024881:Drug Resistance, Bacterial; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000302:isolation & purification; D012189:Retrospective Studies; D012293:Rifampin / Q000494:pharmacology; D014376:Tuberculosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin